China revises registration procedure for imported and high-risk domestic devices:
This article was originally published in Clinica
Executive Summary
China's State Food and Drug Administration (SFDA) has revised the standard registration procedure for all imported medical devices and domestic class III (highest-risk category) devices. Registration now comprises three elements: application acceptance by the SFDA's administrative service centre; a technical assessment, conducted by its Center for Medical Devices Evaluation; and the SFDA's administrative approval. It also specifies registration criteria and time limits, according to a summary statement issued by the agency on July 30.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
England’s NICE Says No To Santhera’s DMD Drug Agamree Due To ‘Unreliable Modeling’
Santhera Pharmaceuticals did not provide enough evidence to demonstrate that its Duchenne muscular dystrophy drug Agamree was a cost-effective use of resources, according to draft guidance from England’s health technology assessment body, NICE.
Timely Acquisition Keeps Germany's Dermapharm Growing
With its Branded Pharmaceuticals division negatively impacted by the end of the COVID-19 pandemic, the timely acquisition of supplements firm Arkopharma ensured Dermapharm recorded double-digit sales growth in 2023.